Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004). This review refines previous concepts into the cancer immunoediting hypothesis, highlighting the role of the immune system in suppressing tumour growth and in shaping tumour immunogenicity.

Article  CAS  PubMed  Google Scholar 

Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1–27 (1970).

Article  CAS  PubMed  Google Scholar 

Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725–729 (1996).

Article  CAS  PubMed  Google Scholar 

Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001). This study shows that the adaptive immune response can prevent tumour formation or lead to a selection of tumour cells with reduced immunogenicity.

Article  CAS  PubMed  Google Scholar 

Monach, P. A., Meredith, S. C., Siegel, C. T. & Schreiber, H. A unique tumor antigen produced by a single amino acid substitution. Immunity 2, 45–59 (1995).

Article  CAS  PubMed  Google Scholar 

Grizzi, F. et al. Cancer-testis antigens and immunotherapy in the light of cancer complexity. Int. Rev. Immunol. 34, 143–153 (2015).

Article  CAS  PubMed  Google Scholar 

Łuksza, M. et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606, 389–395 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Milo, I. et al. The immune system profoundly restricts intratumor genetic heterogeneity. Sci. Immunol. 3, eaat1435 (2018). This preclinical study shows that immune pressure reduces the diversity of genetic mutations and intratumour heterogeneity through the selective elimination of immunogenic tumour cells.

Article  PubMed  Google Scholar 

Dhanasekaran, R. et al. The MYC oncogene — the grand orchestrator of cancer growth and immune evasion. Nat. Rev. Clin. Oncol. 19, 23–36 (2022).

Article  CAS  PubMed  Google Scholar 

Kallingal, A., Olszewski, M., Maciejewska, N., Brankiewicz, W. & Baginski, M. Cancer immune escape: the role of antigen presentation machinery. J. Cancer Res. Clin. Oncol. 149, 8131–8141 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Kim, S. H. et al. The COX2 effector microsomal PGE2 synthase 1 is a regulator of immunosuppression in cutaneous melanoma. Clin. Cancer Res. 25, 1650–1663 (2019).

Article  CAS  PubMed  Google Scholar 

Kohanbash, G. et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Invest. 127, 1425–1437 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Westcott, P. M. K. et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat. Cancer 2, 1071–1085 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188–2205 (2023).

Article  CAS  PubMed  Google Scholar 

McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628 (2017).

Article  CAS  PubMed  Google Scholar 

Boström, M. & Larsson, E. Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer. Nat. Commun. 13, 7023 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Zapata, L. et al. Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors. Nat. Genet. 55, 451–460 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davis, A., Gao, R. & Navin, N. Tumor evolution: linear, branching, neutral or punctuated? Biochim. Biophys. Acta Rev. Cancer 1867, 151–161 (2017).

Article  CAS  PubMed  Google Scholar 

Vendramin, R., Litchfield, K. & Swanton, C. Cancer evolution: Darwin and beyond. EMBO J. 40, e108389 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cindy Yang, S. Y. et al. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat. Commun. 12, 5137 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751–765.e16 (2018). In this longitudinal study of patients with colorectal cancer, branched evolution could be traced back to tumour subclones that evade the immune system owing to tumour-intrinsic and tumour-extrinsic mechanisms.

Article  CAS  PubMed  Google Scholar 

Jiménez-Sánchez, A. et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170, 927–938.e20 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Jiménez-Sánchez, A. et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat. Genet. 52, 582–593 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614.e14 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016). This seminal study demonstrates that the clonality of tumour neoantigens is linked to immune activity, patient outcomes and responsiveness to immune checkpoint blockade therapy.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonald, K. A. et al. Tumor heterogeneity correlates with less immune response and worse survival in breast cancer patients. Ann. Surg. Oncol. 26, 2191–2199 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Nguyen, K. B. et al. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression. eLife 12, e85263 (2023). This study demonstrates that neoantigen heterogeneity in tumour cells is preserved in cross-presenting dendritic cells in the tumour-draining lymph nodes.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolf, A. M. et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606–612 (2003).

PubMed  Google Scholar 

Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).

Article  CAS  PubMed  Google Scholar 

Meyer, M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat. Commun. 9, 1250 (2018).

Article  PubMed  PubMed Central